Figure 2

A) Flowchart showing the screening procedure to assess compounds. B-I) Spectral analyses of heartbeats from hearts treated with various compounds. Spectra from control (DMSO) treatments or untreated hearts are shown in blue, while spectra from compound exposures are shown in red. B-C) Spectra from hearts treated with two different concentrations, as indicated, of clofilium. Spectra from hearts treated with different Ca²⁺ channel modulators D-E), chloride transport inhibitors F-H) and blebbistatin I). Compound concentrations of 10 μM were used in the screen. Data shown in panels B-D, E-G and H-L were generated by three separate screening.